International Rays Treatment Equipment Industry : HALO, CEMI, TGX

New York, NY -- (SBWIRE) -- 12/21/2012 -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) announced today that it has entered into a worldwide Collaboration and License Agreement with Pfizer (PFE) for the purpose of developing and commercializing products combining proprietary Pfizer biologics with Halozyme's Enhanze technology. Halo has been bullish since early trading, trading at an intraday of $6.77 (+22.64%) with over 2.2 million shares that have exchanged hands.

Will HALO continue to pop towards the end of the day? Stick around Here

Chembio Diagnostics, Inc.(NASDAQ:CEMI) stock surged 18.89% to $5.47 after the company announced receipt of approval from the U.S. Food and Drug Administration (FDA) to market the Company’s Dual Path Platform (DPP) HIV 1/2 assay for the rapid, point-of-care (POC) detection of HIV-1/2 antibodies in either oral fluid or blood samples. This determination follows a review of Chembio’s Premarket Approval (PMA) application and marks the first FDA approval of a diagnostic assay utilizing the Company’s patented Dual Path Platform technology.

Should Investors Buy CEMI After The Recent Plunge? Find Out Here

Theragenics Corp. (NYSE:TGX) traded in the range of $1.45 and $1.70 during its latest trading session. The stock had opened at $1.45 and closed at $1.50, up 2.74 percent from its previous close of $1.46. Theragenics Corp. recorded the volume of 999K shares. Its average daily trading volume stands at 37K shares. Its MACD chart shows bullish trend and the stock may go as high as $1.65 in the coming sessions. Its next resistance level is at $1.72. Theragenics Corp. recently entered into a value added loading services agreement with Oncura. The agreement has three years duration.

Get all the tips and hints traders need to successfully invest in TGX by getting the free full report here

DISCLAIMER:

Neither PennyStocksUpdate.biz nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor or broker dealer in any jurisdiction whatsoever and none of the information provided by PennyStocksUpdate.biz, owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or an investment recommendation.PennyStocksUpdate.biz makes no recommendation that the securities of the companies profiled should be purchased, sold or held by individuals or entities that learn of the profiled companies through PennyStocksUpdate.biz. Investing in securities is speculative and carries a high degree of risk and no investment should be made unless you can afford to lose your entire investment. It is possible that an investor's entire investment may be lost or impaired due to the speculative nature of the companies profiled. Please consult a broker before purchasing or selling any securities viewed on or mentioned here in..

Contact:
PennyStocksUpdate.biz
info@pennystocksupdate.biz